APAC Lymphedema Treatment Market - Industry Trends and Forecast to 2031
Asia-Pacific lymphedema treatment market is expected to reach USD 272,372.38 thousand by 2030 from USD 112,385.78 thousand in 2022 growing at the CAGR of 12.0% in the forecast period of 2023 to 2030.
Market Segmentation:
Asia-Pacific Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines , Vietnam, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Veterinary Lymphedema Treatment Market Dynamics:
Driver
• Rising number of lymphedema cases around the globe
Restrain
• High costs of treatment
Opportunity
• Partnership and agreement by market players
Market PlayersSome of the key market players for Asia-Pacific veterinary lymphedema treatment market are listed below:• medi GmbH & Co. KG
• PAUL HARTMANN AG
• 3M
• Convatec Inc.
• JUZO
• SIGVARIS GROUP
• Sanyleg Srl a socio unico
• AIROS Medical, Inc.
• Tactile Medical
• Cardinal Health
• Essity (BSN medical GmbH)
• Smith+Nephew
• Huntleigh Healthcare Limited
• Avet Pharmaceuticals Inc
• KOYA MEDICAL
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.